NRIX · Nurix Therapeutics, Inc.
$23.00
+0.12 (+0.52%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$2.39B
Shares
103.78M
Volume · Oct 5
1.01M
Avg daily vol (3M)
1.26M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$22.88
Open$22.81
Day$22.43–23.31
52W close$9.18–27.79
Avg vol 30d1.4M
Short int18.0M · 17.3% float · 14.1d
Short vol64%
Last earningsJun 8, 2026
DataJul 2020–Oct 2026
Filing10-Q · Jul 9
Up next
Next earnings call
Jun 7, 2027
Est · unconfirmed
· in 35 wks
filed Jul 9, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$36.77M
Trailing 12 months
Net income (TTM)
−$341.35M
Trailing 12 months
Revenue growth YoY
-79.5%
Year over year
Operating margin
-982.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-12.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+32.4%
Year over year · more shares
Price change (1Y)
+153.2%
Trailing year
Short interest
17.3%
Latest settlement · 14.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+17%
above
Price vs 50-day avg
−9%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
+40%
trailing
YTD return
+21%
this year
Relative strength
+29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $20 — 50d above 200d
Institutional flow
Flat
2 of 213 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$246.4K over 90 days · 100% sells
Short interest
Rising
17.32% of float · ▲ +0.1% MoM · 14.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
213 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+99%
Y/Y
EPS growth
−6%
Y/Y
Free cash flow
$-263.5M
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+17%
Bullish
Price vs 50-day avg
−9%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $25 › 200d $20 — 50d above 200d
Institutional flow
Flat
2 of 213 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$246.4K over 90 days · 100% sells
Short interest
Rising
17.32% of float · ▲ +0.1% MoM · 14.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
213 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $23 · 74%
Range high $28
vs 200-day avg +17%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRIX
this stock
Nurix Therapeutics, Inc.
|
$2.39B | +20.6% | +99.3% | — | 17.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRIX | -3.3% | -12.5% | +40.4% | -3.5% | +20.6% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -4.5% | -13.1% | +28.8% | -5.1% | +7.0% |